Add To Watchlist
Share URL
About The Company
Description
BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States.
Read More
Overview
Value
1
Growth
18
Health
25
Management
70
Analyst Opinion
46
Total
32
All Scores Out Of 100
Best Features
- Has a low level of debt
- Low preportion of income is paid as dividend
Risk Factors
- Overvalued on cashflow basis
- Earnings have declined recently
- Income is not covering expenditure and investment
- Earnings are negative
- There is a history of diluting shareholders 0
- Does not hold enough liquid assets to cover short term liabilities
- Poor overall financial health
- No margin of safety at their current market price
- Poor earnings and cashflow growth 0
Latest News
BioCorRx to Present at Sequire Biotechnology Conference on February 2nd
GlobeNewsWire | 13:30 Fri 27 Jan 2023
Read More →
BioCorRx to Present at the LD Micro Main Event XV on October 25th
Newsfile Corp | 17:30 Mon 24 Oct 2022
Read More →
BioCorRx to Present at the H.C. Wainwright 24th Annual Global Investment Conference
GlobeNewsWire | 14:30 Tue 6 Sept 2022
Read More →
BioCorRx to Present at the LD Micro Invitational XII on June 7th
GlobeNewsWire | 15:00 Tue 31 May 2022
Read More →
Market Peers
BICX
Key Figures
PE Ratio (TTM)
N/A
Margin Of Safety (DCF)
-187.10%
Revenue Growth (5 Year Average)
-20.52%
Ratings Consensus
Sell
Share Buybacks
-37.33%
Dividend Yeild (TTM)
N/A
Valuation
Value Score
1
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: N/A✘
Current Price: 1.8 USD
Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
N/Ax
Free Cashflow Yeild
-16.70%
PE/Earnings Growth
N/A
Price/Book
-1.87x
Growth
Growth Score
18
- ✔ Revenue growth has improved this yeara
- ✔ 5 Year Average Earnings growth of 21.67% is higher than the market average (14.48%)
- ✔ Free Cashflow growth has improved this year
- ✘ 5 Year Average Revenue growth of -20.52% is lower than the market average (10.97%)
- ✘ Earnings growth has slowed this year
- ✘ 5 Year Average Free Cashflow growth of -3.31% is lower than the market average (12.35%)
Revenue Growth
-20.52%
Earnings Growth
21.67%
Cashflow Growth
-3.31%
Health
Health Score
25
Altman Z Score
N/A
Piostroski Score
4.00
Debt/Equity
N/Ax
Current Assets/Liabilities
0.05x
Free Cashflow/Total Debt
N/Ax
Debt/Capital
7.24x
Management
Management Score
70
Average Buybacks/Dilution
-37.33%
Recent Buybacks/Dilution
17.52%
5 Year Price Volitility
79.63%
Return On Assets
-753.55%
Return On Capital Employed
-82.68%
Return On Equity
90.29%
Return On Free Cashflow
285.92%
Return On Investments
N/A
Analysts
Analyst Opinion
46
- ✘ Ratings consensus is Sell
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
BioCorRx Inc.
Currency
USD
Beta
0.884548
Vol Avg
2496
Ceo
Ms. Lourdes Felix
Cik
0001443863
Cusip
09073C205
Exchange
Other OTC
Full Time Employees
Industry
Medical Care Facilities
Sector
Healthcare
Ipo Date
2010-09-01
Address
2390 East Orangewood Avenue
City
Anaheim
State
CA
Country
US
Zip
92806
Phone
714 462 4880
All financial data provided by FMP